WOCKPHARMA.NS
Wockhardt Limited [WOCKPHARMA.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
WOCKPHARMA.NS Stock Summary
Top 10 Correlated Stocks
WOCKPHARMA.NS
In the News
WOCKPHARMA.NS Financial details
Company Rating
Neutral
Market Cap
85.2B
Income
-5.31B
Revenue
27.76B
Book val./share
238.17
Cash/share
7.98
Dividend
-
Dividend %
-
Employees
2.74K
Optionable
No
Shortable
Yes
Earnings
24 May 2024
P/E
-12.03
Forward P/E
-
PEG
-2.03
P/S
2.4
P/B
2.12
P/C
73.04
P/FCF
6649.98
Quick Ratio
0.42
Current Ratio
0.76
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-36.85
EPS next Y
-
EPS next Q
-
EPS this Y
86.3%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
21.62%
Revenue last 5Y
-8.53%
Revenue Q/Q
-6.91%
EPS Q/Q
7.87%
-
-
-
-
SMA20
5.36%
SMA50
26.39%
SMA100
77.02%
Inst Own
-
Inst Trans
-
ROA
-7%
ROE
-34%
ROC
-0.01%
Gross Margin
57%
Oper. Margin
-1%
Profit Margin
-20%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
165.0-630.0
52W High
-7.48%
52W Low
+253.24%
RSI
55
Rel Volume
0.46
Avg Volume
1.1M
Volume
507.34K
Perf Week
1.61%
Perf Month
-4.56%
Perf Quarter
165.41%
Perf Half Y
136.4%
-
-
-
-
Beta
1.623
-
-
Volatility
16.16%, 23.98%
Prev Close
1.73%
Price
582.85
Change
6.36%
WOCKPHARMA.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 344.74 | 235.8 | 224.59 | 266.26 | 184.02 | |
| Net income per share | -16.2 | -11.48 | -24.69 | -23.14 | -43.11 | |
| Operating cash flow per share | 15.27 | 54.01 | -23.91 | 34.26 | 10.62 | |
| Free cash flow per share | -7.62 | 39.67 | -37.7 | 16.67 | -3.89 | |
| Cash per share | 36.9 | 22.06 | 19.78 | 31.44 | 10.41 | |
| Book value per share | 222.74 | 222.37 | 280.96 | 319.26 | 232.81 | |
| Tangible book value per share | 127.03 | 107.03 | 162.46 | 187.29 | 105.3 | |
| Share holders equity per share | 222.74 | 222.37 | 280.96 | 319.26 | 232.81 | |
| Interest debt per share | 302.67 | 320.6 | 242.63 | 205.71 | 172.56 | |
| Market cap | 54.64B | 20.74B | 49.76B | 31.78B | 22.17B | |
| Enterprise value | 84.41B | 54.37B | 74.17B | 50.06B | 43.11B | |
| P/E ratio | -28.09 | -15.04 | -16.77 | -11.39 | -3.57 | |
| Price to sales ratio | 1.32 | 0.73 | 1.84 | 0.99 | 0.84 | |
| POCF ratio | 29.81 | 3.2 | -17.32 | 7.69 | 14.49 | |
| PFCF ratio | -59.68 | 4.35 | -10.98 | 15.81 | -39.59 | |
| P/B Ratio | 2.04 | 0.78 | 1.47 | 0.83 | 0.66 | |
| PTB ratio | 2.04 | 0.78 | 1.47 | 0.83 | 0.66 | |
| EV to sales | 2.04 | 1.92 | 2.75 | 1.56 | 1.63 | |
| Enterprise value over EBITDA | 67.67 | 41.03 | -364.47 | 16.63 | 19.33 | |
| EV to operating cash flow | 46.05 | 8.38 | -25.81 | 12.12 | 28.18 | |
| EV to free cash flow | -92.2 | 11.41 | -16.37 | 24.91 | -76.98 | |
| Earnings yield | -0.04 | -0.07 | -0.06 | -0.09 | -0.28 | |
| Free cash flow yield | -0.02 | 0.23 | -0.09 | 0.06 | -0.03 | |
| Debt to equity | 1.26 | 1.34 | 0.79 | 0.57 | 0.65 | |
| Debt to assets | 0.43 | 0.44 | 0.34 | 0.27 | 0.28 | |
| Net debt to EBITDA | 23.87 | 25.37 | -119.94 | 6.07 | 9.39 | |
| Current ratio | 0.98 | 0.69 | 0.78 | 0.81 | 0.64 | |
| Interest coverage | -0.12 | -0.35 | -1.1 | 0.19 | -0.09 | |
| Income quality | -0.61 | -3.3 | -0.31 | -1 | -0.25 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | -0.01 | 0 | |
| Sales general and administrative to revenue | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 | |
| Research and developement to revenue | 0.07 | 0.07 | 0.06 | 0.04 | 0.05 | |
| Intangibles to total assets | 0.19 | 0.22 | 0.23 | 0.24 | 0.28 | |
| Capex to operating cash flow | -1.5 | -0.27 | 0.58 | -0.51 | -1.37 | |
| Capex to revenue | -0.07 | -0.06 | -0.06 | -0.07 | -0.08 | |
| Capex to depreciation | -1.66 | -0.76 | -0.67 | -0.86 | -0.83 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 284.93 | 239.68 | 395.07 | 407.72 | 475.18 | |
| ROIC | 0 | -0.01 | -0.02 | 0.01 | 0 | |
| Return on tangible assets | -0.03 | -0.02 | -0.05 | -0.04 | -0.11 | |
| Graham Net | -245.7 | -297.37 | -209.13 | -203.36 | -189.06 | |
| Working capital | -490.1M | -10.67B | -6.94B | -6.18B | -12.27B | |
| Tangible asset value | 15.25B | 12.86B | 19.52B | 22.58B | 15.17B | |
| Net current asset value | -20.25B | -26.92B | -15.88B | -14.52B | -18.13B | |
| Invested capital | 1.26 | 1.34 | 0.79 | 0.57 | 0.65 | |
| Average receivables | 12.06B | 13.08B | 12B | 11.25B | 10.96B | |
| Average payables | 7.21B | 8.68B | 7.37B | 7.49B | 8.94B | |
| Average inventory | 8.38B | 7.55B | 7.44B | 7.84B | 7.14B | |
| Days sales outstanding | 120.27 | 161.25 | 155.4 | 125.19 | 150.21 | |
| Days payables outstanding | 169.01 | 271.53 | 185.79 | 265.32 | 284.84 | |
| Days of inventory on hand | 164.81 | 209.22 | 256.8 | 221.54 | 216.17 | |
| Receivables turnover | 3.03 | 2.26 | 2.35 | 2.92 | 2.43 | |
| Payables turnover | 2.16 | 1.34 | 1.96 | 1.38 | 1.28 | |
| Inventory turnover | 2.21 | 1.74 | 1.42 | 1.65 | 1.69 | |
| ROE | -0.07 | -0.05 | -0.09 | -0.07 | -0.19 | |
| Capex per share | -22.89 | -14.35 | -13.79 | -17.58 | -14.51 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 48.52 | 47.05 | 44.69 | 52.26 | 48.65 | |
| Net income per share | -7.08 | -16.45 | -9.3 | -5.34 | -5.76 | |
| Operating cash flow per share | 9.16 | 0.07 | 7.63 | 7.63 | 7.63 | |
| Free cash flow per share | 9.16 | 0.07 | 7.63 | 7.63 | 7.63 | |
| Cash per share | 16.24 | 10.41 | 8.05 | 7.98 | 7.98 | |
| Book value per share | 266.35 | 232.77 | 254.14 | 216.87 | 238.17 | |
| Tangible book value per share | 0 | 105.28 | 0 | 86.33 | 0 | |
| Share holders equity per share | 266.35 | 232.77 | 254.14 | 216.87 | 238.17 | |
| Interest debt per share | 5.76 | 156.85 | 5.48 | 163.09 | 5.34 | |
| Market cap | 32.13B | 22.18B | 33.93B | 33.9B | 67.68B | |
| Enterprise value | 34.47B | 43.12B | 35.09B | 56.1B | 68.83B | |
| P/E ratio | -7.88 | -2.34 | -6.33 | -11.01 | -20.39 | |
| Price to sales ratio | 4.6 | 3.27 | 5.27 | 4.5 | 9.66 | |
| POCF ratio | 24.34 | 2.22K | 30.84 | 30.82 | 61.53 | |
| PFCF ratio | 24.34 | 2.22K | 30.84 | 30.82 | 61.53 | |
| P/B Ratio | 0.84 | 0.66 | 0.93 | 1.08 | 1.97 | |
| PTB ratio | 0.84 | 0.66 | 0.93 | 1.08 | 1.97 | |
| EV to sales | 4.93 | 6.36 | 5.45 | 7.45 | 9.82 | |
| Enterprise value over EBITDA | 73.35 | 123.19 | 116.96 | 58.44 | 152.97 | |
| EV to operating cash flow | 26.12 | 4.31K | 31.9 | 51 | 62.58 | |
| EV to free cash flow | 26.12 | 4.31K | 31.9 | 51 | 62.58 | |
| Earnings yield | -0.03 | -0.11 | -0.04 | -0.02 | -0.01 | |
| Free cash flow yield | 0.04 | 0 | 0.03 | 0.03 | 0.02 | |
| Debt to equity | 0 | 0.65 | 0 | 0.73 | 0 | |
| Debt to assets | 0 | 0.28 | 0 | 0.31 | 0 | |
| Net debt to EBITDA | 4.98 | 59.83 | 3.87 | 23.13 | 2.56 | |
| Current ratio | 0 | 0.64 | 0 | 0.76 | 0 | |
| Interest coverage | -0.23 | -0.28 | -0.32 | 0.54 | -0.13 | |
| Income quality | -1.38 | 0 | -0.82 | -1.43 | -1.33 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.06 | 0.04 | 0.06 | 0.05 | 0.04 | |
| Intangibles to total assets | 0 | 0.28 | 0 | 0.29 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 205.99 | 293.51 | 230.6 | 161.48 | 175.69 | |
| ROIC | 0 | 0 | -0.01 | 0.02 | 0 | |
| Return on tangible assets | 0 | -0.04 | 0 | -0.01 | 0 | |
| Graham Net | 16.24 | -189.03 | 8.05 | -194.07 | 7.98 | |
| Working capital | 2.34B | -12.27B | 1.16B | -6.48B | 1.15B | |
| Tangible asset value | 0 | 15.17B | 0 | 12.44B | 0 | |
| Net current asset value | 2.34B | -18.13B | 1.16B | -19.51B | 1.15B | |
| Invested capital | 0 | 0.65 | 0 | 0.73 | 0 | |
| Average receivables | 4.8B | 5.46B | 5.46B | 5.06B | 5.06B | |
| Average payables | 3.7B | 4.34B | 4.34B | 4B | 4B | |
| Average inventory | 3.74B | 3.29B | 3.29B | 3.18B | 3.18B | |
| Days sales outstanding | 0 | 144.82 | 0 | 120.96 | 0 | |
| Days payables outstanding | 0 | 255 | 0 | 250.87 | 0 | |
| Days of inventory on hand | 0 | 193.53 | 0 | 199.13 | 0 | |
| Receivables turnover | 0 | 0.62 | 0 | 0.74 | 0 | |
| Payables turnover | 0 | 0.35 | 0 | 0.36 | 0 | |
| Inventory turnover | 0 | 0.47 | 0 | 0.45 | 0 | |
| ROE | -0.03 | -0.07 | -0.04 | -0.02 | -0.02 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
WOCKPHARMA.NS Frequently Asked Questions
What is Wockhardt Limited stock symbol ?
Wockhardt Limited is a IN stock and trading under the symbol WOCKPHARMA.NS
What is Wockhardt Limited stock quote today ?
Wockhardt Limited stock price is $582.85 today.
Is Wockhardt Limited stock public?
Yes, Wockhardt Limited is a publicly traded company.
Company Profile
- Volume Average 1.1M
- Market Capitalization 85.2B
- Employee 2.74K
- CEO Dr. Habil Fakhruddin Khorakiwala
- Headquarters Mumbai,IN
- IPO Date 2002-07-01
-
Website
https://www.wockhardt.com 
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.
